OncRef

Clinical Trial: NCT00053898

Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:NSABP Foundation Inc
Information Provided By:NSABP Foundation Inc
Last Update Posted:2018-09-20

Study Overview

Brief Summary

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Tamoxifen may fight breast cancer by blocking the use of estrogen. Anastrozole may fight breast cancer by decreasing estrogen production. It is not yet known whether anastrozole is more effective than tamoxifen in preventing the recurrence of breast cancer.

PURPOSE: This randomized phase III trial is studying anastrozole to see how well it works compared to tamoxifen in preventing the recurrence of breast cancer in postmenopausal women with ductal carcinoma in situ who are undergoing lumpectomy and radiation therapy.

Official Title

A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy

Conditions

Breast Cancer

Intervention / Treatment

  • Drug: anastrozole
  • Drug: tamoxifen citrate
  • Radiation: Radiation Therapy

Other Study ID Numbers

  • NSABP B-35
  • NSABP-B-35
  • SWOG-NSABP-B-35
  • NCCTG-NSABP-B-35
  • ACOSOG-NSABP-B-35

Start Date

2003-01

Primary Completion Date (Actual)

2015-03

Study Completion Date (Actual)

2016-05

Enrollment (Actual)

3104

Study Type

Interventional

Phase

Phase 3